Eight patients had a complete response within 1 month of infusion.
All articles by Leah Lawrence
The model appears to predict minimal residual disease status.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
The bispecific CAR-T therapy targets CD20 and CD19.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
Dr Samur and colleagues found that high-dose melphalan caused an approximately 2.5-fold greater mutation accumulation rate than that observed with RVD treatment alone.
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.
Census tract affluence, disadvantage, and segregation were all significant predictors of leukemia-related death.
Latest News Your top articles for SaturdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses